



## Clinical trial results:

**Multinational, Randomized, Double Blind, Comparative Study to Evaluate The Efficacy and Safety of Telithromycin, 800 mg Once Daily for 5 Days, Versus Penicillin V, 500 mg Three Times Daily for 10 Days, In Adolescent and Adult Subjects Equal to or Over 13 Years of Age With Streptococcus Pyogenes Tonsillitis/Pharyngitis**

## Summary

EudraCT number	2014-004631-39
Trial protocol	Outside EU/EEA
Global end of trial date	20 September 2007

## Results information

Result version number	v1 (current)
This version publication date	23 May 2016
First version publication date	28 June 2015

## Trial information

### Trial identification

Sponsor protocol code	EFC6134, HMR3647B/3006
-----------------------	------------------------

### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00315549
WHO universal trial number (UTN)	-

Notes:

## Sponsors

Sponsor organisation name	Sanofi U.S Services Inc.
Sponsor organisation address	55 Corporate Drive Bridgewater, New Jersey, United States, 08807
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement , Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement , Contact-US@sanofi.com

Notes:

## Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 June 2008
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	20 September 2007
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Primary objective of this study was to compare the bacteriologic efficacy of 5 days of telithromycin to 10 days of penicillin V in subjects with baseline bacterial throat culture positive for *Streptococcus pyogenes* (*S. pyogenes*) and repeat throat culture performed at the posttherapy/test-of-cure visit (Visit 3, Days 13 to 17) in the per-protocol population for analysis of bacteriologic outcome (PPb).

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency.

Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

The study was conducted by investigators experienced in the treatment of pediatric subjects. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), an assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 February 2006
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 233
Worldwide total number of subjects	233
EEA total number of subjects	0

Notes:

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	79
Adults (18-64 years)	153
From 65 to 84 years	1
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 41 sites in United States of America. A total of 256 subjects were screened between 20 February 2006 and 7 June 2006.

### Pre-assignment

Screening details:

Of 256 screened subjects, 233 subjects were randomized.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Telithromycin
------------------	---------------

Arm description:

Telithromycin for 5 days and placebo for 10 days.

Arm type	Experimental
Investigational medicinal product name	Telithromycin
Investigational medicinal product code	HMR3647
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Telithromycin tablet over-encapsulated 800 mg once daily.

Investigational medicinal product name	Placebo (for Penicillin V)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo matched to Penicillin V 3 times daily for 10 days.

<b>Arm title</b>	Penicillin V
------------------	--------------

Arm description:

Penicillin V for 10 days and placebo for 5 days.

Arm type	Active comparator
Investigational medicinal product name	Penicillin V potassium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Penicillin V tablet over-encapsulated 500 mg three times daily.

Investigational medicinal product name	Placebo (for Telithromycin)
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo matched to Telithromycin once daily for 5 days.

<b>Number of subjects in period 1</b>	Telithromycin	Penicillin V
Started	112	121
Treated	112	120
Completed	97	103
Not completed	15	18
Consent withdrawn by subject	2	-
Randomized but not treated	-	1
Adverse event	7	5
Unspecified	-	2
Lost to follow-up	5	6
Lack of efficacy	1	4

## Baseline characteristics

### Reporting groups

Reporting group title	Telithromycin
-----------------------	---------------

Reporting group description:

Telithromycin for 5 days and placebo for 10 days.

Reporting group title	Penicillin V
-----------------------	--------------

Reporting group description:

Penicillin V for 10 days and placebo for 5 days.

Reporting group values	Telithromycin	Penicillin V	Total
Number of subjects	112	121	233
Age categorical Units: Subjects			
Adolescents (12-17 years)	37	42	79
Adults (18-64 years)	75	78	153
From 65-84 years	0	1	1
Gender categorical Units: Subjects			
Female	77	76	153
Male	35	44	79
Not available	0	1	1

## End points

### End points reporting groups

Reporting group title	Telithromycin
Reporting group description: Telithromycin for 5 days and placebo for 10 days.	
Reporting group title	Penicillin V
Reporting group description: Penicillin V for 10 days and placebo for 5 days.	

### Primary: Percentage of Subjects According to Bacteriological Outcome in Bacteriological Per Protocol (PPb) Population

End point title	Percentage of Subjects According to Bacteriological Outcome in Bacteriological Per Protocol (PPb) Population <sup>[1]</sup>
End point description: Bacteriologic cure was defined as eradication of <i>S. pyogenes</i> at postbaseline culture (documented eradication). Bacteriologic failure was defined to occur if after 72 hours of study medication, a subject had a positive repeat postbaseline throat culture for <i>S. pyogenes</i> . The PPb population was defined as the per protocol population for analysis of bacteriologic outcome. The PPb population contained all subjects of the clinical per protocol population (PPc) population with isolation of <i>S. pyogenes</i> at Visit 1 and a postbaseline culture at the Visit 3 and/or Visit 4 time window excluding the major protocol violations. Bacteriologic outcome assessment was made for the visit window in which the culture was obtained.	
End point type	Primary
End point timeframe: At post therapy (Day 13-17)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated early (randomization of 233 subjects/760 planned) the type II error was not controlled as planned and only descriptive statistics were generated.

End point values	Telithromycin	Penicillin V		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	84		
Units: percentage of subjects				
number (not applicable)				
Bacteriologic Cure (Documented Eradication)	93	83.3		
Bacteriologic Failure (Documented Persistence)	7	16.7		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects According to Bacteriological Outcome in Bacteriological Modified Intent to Treat (mITTb) Population

End point title	Percentage of Subjects According to Bacteriological Outcome in Bacteriological Modified Intent to Treat (mITTb) Population
-----------------	--

End point description:

Analysis was carried out on bmITT population defined as the bacteriological modified intent to treat population that included all subjects that were in the mITT population with isolation of *S. pyogenes* at Visit 1.

End point type	Secondary
----------------	-----------

End point timeframe:

At post therapy (Day 13-17)

End point values	Telithromycin	Penicillin V		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	96		
Units: percentage of subjects				
number (not applicable)				
Bacteriologic Cure (Documented Eradication)	85.7	77.1		
Bacteriologic Failure (Documented Persistence)	7.1	14.6		
Bacteriologic Indeterminate	7.1	8.3		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects According to Bacteriological Outcome in PPb Population (At Late Post Therapy)

End point title	Percentage of Subjects According to Bacteriological Outcome in PPb Population (At Late Post Therapy)
-----------------	--

End point description:

Bacteriologic cure was defined as eradication of *S. pyogenes* at postbaseline culture (documented eradication). Bacteriologic failure was defined to occur if after 72 hours of study medication, a subject had a positive repeat Postbaseline throat culture for *S. pyogenes*. Analysis was performed on PPb population. Number of subjects analysed = subjects with data available at Day 38-45.

End point type	Secondary
----------------	-----------

End point timeframe:

At late post therapy (Day 38-45)

End point values	Telithromycin	Penicillin V		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56	67		
Units: percentage of subjects				
number (not applicable)				
Bacteriologic Cure (Documented Eradication)	94.6	91		
Bacteriologic Failure (Documented Persistence)	5.4	9		



## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Adverse Events of Special Interest

End point title	Number of Subjects with Adverse Events of Special Interest
-----------------	--

End point description:

Analysis was carried out on safety population which included all randomized and treated subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

7 days after end of treatment

End point values	Telithromycin	Penicillin V		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	112	120		
Units: subjects				
Cardiac events	0	0		
Hepatic events	5	2		
Visual disturbances	3	3		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Days 38-45) regardless of seriousness or relationship to investigational product. Analysis was performed on safety population.

Adverse event reporting additional description:

Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (first dose of study medication and up to 7 days after the last dose of study medication or, up to 17 days after the first dose of study medication, whichever is later).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	10.1

### Reporting groups

Reporting group title	Penicillin
-----------------------	------------

Reporting group description:

Penicillin V for 10 days and placebo for 5 days.

Reporting group title	Telithromycin
-----------------------	---------------

Reporting group description:

Telithromycin for 5 days and placebo for 10 days.

Serious adverse events	Penicillin	Telithromycin	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 120 (0.83%)	1 / 112 (0.89%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Investigations			
Liver Function Test Abnormal			
subjects affected / exposed	0 / 120 (0.00%)	1 / 112 (0.89%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual Tracking Test Abnormal			
subjects affected / exposed	1 / 120 (0.83%)	0 / 112 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Serum Sickness			

subjects affected / exposed	0 / 120 (0.00%)	1 / 112 (0.89%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Acute Sinusitis			
subjects affected / exposed	1 / 120 (0.83%)	0 / 112 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Penicillin	Telithromycin	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 120 (1.67%)	11 / 112 (9.82%)	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 120 (1.67%)	11 / 112 (9.82%)	
occurrences (all)	2	14	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
27 June 2006	In June 2006, the Sponsor voluntarily paused enrollment in pediatric clinical trials with no subsequent recruitment of subjects. On 20 September 2007, the Sponsor informed the study sites that the trial was terminated.	-

Notes:

### Limitations and caveats

None reported